For decades, induction and maintenance intravesical therapy with bacillus Calmette-Guérin (BCG) has served as the foundation for management of high-risk non–muscle invasive bladder cancer (NMIBC) [1]. In this issue of European Urology, two trials challenge that paradigm and introduce unique approaches that include treatment de-escalation for select patients and a novel protocol requiring fewer doses of BCG.
For decades, induction and maintenance intravesical therapy with bacillus Calmette-Guérin (BCG) has served as the foundation for management of high-risk non–muscle invasive bladder cancer (NMIBC) [1]. In this issue of European Urology, two trials challenge that paradigm and introduce unique approaches that include treatment de-escalation for select patients and a novel protocol requiring fewer doses of BCG.